194 related articles for article (PubMed ID: 26386615)
1. Study of Ki67 and CD10 expression as predictive factors of recurrence of ameloblastoma.
Ahlem B; Wided A; Amani L; Nadia Z; Amira A; Faten F
Eur Ann Otorhinolaryngol Head Neck Dis; 2015 Nov; 132(5):275-9. PubMed ID: 26386615
[TBL] [Abstract][Full Text] [Related]
2. EGFR, CD10 and proliferation marker Ki67 expression in ameloblastoma: possible role in local recurrence.
Abdel-Aziz A; Amin MM
Diagn Pathol; 2012 Feb; 7():14. PubMed ID: 22300665
[TBL] [Abstract][Full Text] [Related]
3. CD10 expression in stromal cells of ameloblastoma variants.
Iezzi G; Piattelli A; Rubini C; Artese L; Goteri G; Fioroni M; Carinci F
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2008 Feb; 105(2):206-9. PubMed ID: 17942343
[TBL] [Abstract][Full Text] [Related]
4. CD10 and osteopontin expression in dentigerous cyst and ameloblastoma.
Masloub SM; Abdel-Azim AM; Elhamid ES
Diagn Pathol; 2011 May; 6():44. PubMed ID: 21609487
[TBL] [Abstract][Full Text] [Related]
5. A comparative study of bone remodeling molecules expression in different types of jaw ameloblastoma.
Iakovou M; Chrysomali E; Piperi E; Fanourakis G; Sklavounou A; Vlachodimitropoulos D; Tseleni-Balafouta S
J Oral Pathol Med; 2015 Aug; 44(7):543-51. PubMed ID: 25243582
[TBL] [Abstract][Full Text] [Related]
6. [Expression of Ki-67 antigen in ameloblastoma and its clinical significance].
Han B; Li L; Wang H
Hua Xi Kou Qiang Yi Xue Za Zhi; 2003 Apr; 21(2):153-4. PubMed ID: 12838707
[TBL] [Abstract][Full Text] [Related]
7. Prognostic impact of CD10 expression in clinical outcome of invasive breast carcinoma.
Vo TN; Mekata E; Umeda T; Abe H; Kawai Y; Mori T; Kubota Y; Shiomi H; Naka S; Shimizu T; Murata S; Yamamoto H; Ishida M; Tani T
Breast Cancer; 2015 Mar; 22(2):117-28. PubMed ID: 23575921
[TBL] [Abstract][Full Text] [Related]
8. Invadopodia proteins, cortactin, N-WASP and WIP differentially promote local invasiveness in ameloblastoma.
Siar CH; Rahman ZA; Tsujigiwa H; Mohamed Om Alblazi K; Nagatsuka H; Ng KH
J Oral Pathol Med; 2016 Sep; 45(8):591-8. PubMed ID: 26752341
[TBL] [Abstract][Full Text] [Related]
9. Cell proliferation proteins and aggressiveness of histological variants of ameloblastoma and keratocystic odontogenic tumor.
Gupta K; Chaturvedi TP; Gupta J; Agrawal R
Biotech Histochem; 2019 Jul; 94(5):348-351. PubMed ID: 30806083
[TBL] [Abstract][Full Text] [Related]
10. Ameloblastoma in Jamaica--predominantly unicystic: analysis of 47 patients over a 16-year period and a case report on re-entry cryosurgery as a new modality of treatment for the prevention of recurrence.
Ogunsalu C; West W; Lewis A; Williams N
West Indian Med J; 2011 Mar; 60(2):240-6. PubMed ID: 21942138
[TBL] [Abstract][Full Text] [Related]
11. Is podoplanin expression associated with the proliferative activity of ameloblastomas?
Tjioe KC; Oliveira DT; Soares CT; Lauris JR; Damante JH
Oral Dis; 2012 Oct; 18(7):673-9. PubMed ID: 22443371
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical expression of K6, K8, K16, K17, K19, maspin, syndecan-1 (CD138), α-SMA, and Ki-67 in ameloblastoma and ameloblastic carcinoma: diagnostic and prognostic correlations.
Safadi RA; Quda BF; Hammad HM
Oral Surg Oral Med Oral Pathol Oral Radiol; 2016 Apr; 121(4):402-11. PubMed ID: 26972539
[TBL] [Abstract][Full Text] [Related]
13. A immunohistochemical study of the peripheral ameloblastoma.
Kishino M; Murakami S; Yuki M; Iida S; Ogawa Y; Kogo M; Toyosawa S
Oral Dis; 2007 Nov; 13(6):575-80. PubMed ID: 17944675
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical biomarkers in ameloblastomas.
do Canto AM; Rozatto JR; Schussel JL; de Freitas RR; Hasséus B; Braz-Silva PH
Acta Odontol Scand; 2016 Nov; 74(8):585-590. PubMed ID: 27571891
[TBL] [Abstract][Full Text] [Related]
15. Ameloblastoma and adenomatoid odontogenic tumor: the role of alpha2beta1, alpha3beta1, and alpha5beta1 integrins in local invasiveness and architectural characteristics.
Souza Andrade ES; da Costa Miguel MC; Pinto LP; de Souza LB
Ann Diagn Pathol; 2007 Jun; 11(3):199-205. PubMed ID: 17498594
[TBL] [Abstract][Full Text] [Related]
16. The evaluation of p16 and Ki67 immunoexpression in ameloblastomas.
Olimid DA; Florescu AM; Cernea D; Georgescu CC; Mărgăritescu C; Simionescu CE; Stepan AE
Rom J Morphol Embryol; 2014; 55(2):363-7. PubMed ID: 24969987
[TBL] [Abstract][Full Text] [Related]
17. Expression of proliferative markers in ameloblastomas and malignant odontogenic tumors.
Otero D; Lourenço SQ; Ruiz-Ávila I; Bravo M; Sousa T; de Faria PA; González-Moles MA
Oral Dis; 2013 May; 19(4):360-5. PubMed ID: 22970847
[TBL] [Abstract][Full Text] [Related]
18. Expression of midkine in ameloblastomas and its correlation with clinicopathologic parameters.
Scheper MA; Duarte EC; Intapa C; Zhang M; Nascimento LM; Almeida TP; Gomes AC; Song S; Chaisuparat R; Batista AC; Jham BC
Oral Surg Oral Med Oral Pathol Oral Radiol; 2012 Oct; 114(4):497-502. PubMed ID: 22986245
[TBL] [Abstract][Full Text] [Related]
19. Tissue microarray use for immunohistochemical study of ameloblastoma.
Neves-Silva R; Fonseca FP; de Jesus AS; Pontes HA; Rocha AC; Brandão TB; Vargas PA; Lopes MA; de Almeida OP; Santos-Silva AR
J Oral Pathol Med; 2016 Oct; 45(9):704-711. PubMed ID: 26841348
[TBL] [Abstract][Full Text] [Related]
20. Matrix metalloproteinases, TIMPs and growth factors regulating ameloblastoma behaviour.
Siqueira AS; Carvalho MR; Monteiro AC; Freitas VM; Jaeger RG; Pinheiro JJ
Histopathology; 2010 Jul; 57(1):128-37. PubMed ID: 20653784
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
